Antihemophilic Factor, Human Recombinant 1 UNT Injection [Helixate]

Known as: ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT 250 [iU] in 2.5 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [Helixate FS], Helixate FS 1 UNT Injection, Helixate FS KIT 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2007-2018
01220072018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
BACKGROUND Patients with severe haemophilia A who have been treated extensively with factor VIII (FVIII) products face a low but… (More)
Is this relevant?
2017
2017
BACKGROUND To compare changes in higher-order aberrations (HOAs) following small incision lenticule extraction (SMILE) and… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2016
2016
AIM To develop algorithms for detecting significant fibrosis and cirrhosis in chronic hepatitis B (CHB) patients with the aim of… (More)
Is this relevant?
2014
2014
The objective of this study was to evaluate the inhibitor development (ID) in previously untreated patients (PUPs) with severe… (More)
Is this relevant?
2014
2014
OBJECTIVE This study aimed to quantify functional status (FS) trajectories pre- and post-diagnosis of cancer, FS trajectories… (More)
Is this relevant?
2011
2011
OBJECTIVE To evaluate the association between biomarkers of inflammation and endothelial dysfunction and Framingham scores (FS… (More)
Is this relevant?
2007
2007
In our previous study, flaxseed (FS) reduced while soy protein isolate (SPI) stimulated MCF-7 breast tumor growth in… (More)
Is this relevant?
2007
2007
The use of plasma-derived products has contributed to a high rate of blood-borne infections among haemophilia patients in China… (More)
Is this relevant?